{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-147538","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.688321+00:00","generated_at":"2026-06-25T21:11:29.426366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance","bullets":["Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.","GAAP net loss of $2.2M vs net income of $0.1M last year; operating loss $2.4M vs income $1.1M.","Adjusted EBITDA $1.9M, up from $1.1M; adjusted gross margin 61% vs 60%.","FY2022 revenue guidance raised to high end of $160M-$168M range.","Service revenue more than doubled from prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-147538","json":"https://secwatch.observer/filing/0001193125-22-147538.json","markdown":"https://secwatch.observer/filing/0001193125-22-147538.md","text":"https://secwatch.observer/filing/0001193125-22-147538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/0001193125-22-147538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/d315155d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:11:29.426366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}